XML 31 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Cash flows from operating activities:      
Net loss $ (12,545) $ (8,052) $ (3,013)
Adjustments to reconcile net loss to cash used in operating activities:      
Excess cost for acquisition of an equity investee 814
Net loss on equity method investment 44 97
Imputed interest 532 826
Depreciation expenses 18 10 0
Loss on disposal of property and equipment 27
Changes in assets and liabilities:      
Advances to suppliers (710) (73) (16)
Prepaid expenses and other current assets (334) (22) (2)
Other noncurrent assets (121)
Accounts payable 144 94 45
Due to related parties (222) (168) 870
Accrued expenses (102) 210
Other current liabilities 174 14 47
Net cash used in operating activities (13,698) (6,570) (1,146)
Cash flows from investing activities:      
Acquisitions of property and equipment (64) (40)
Loans to related parties (861) (960)
Cash obtained from acquisition of an equity investee 1,256
Net cash (used in) provided by investing activities (64) 355 (960)
Cash flows from financing activities:      
Proceeds from issuance of ordinary shares 15,250 16,000
Proceeds from a third party loan 1,000
Proceeds from loans due to related parties 1,273 2,498
Repayment of loans due to related parties (402)
Cash distribution to equity owner in the Internal Restructuring (1,201)
Payment of initial public offering costs (537)
Net cash provided by financing activities 14,713 16,670 2,498
Effect of foreign exchange rate changes (85) (26) (8)
Net increase in cash and cash equivalents 866 10,429 384
Cash at beginning of year 10,821 392 8
Cash at end of year 11,687 10,821 392
Non-cash activities:      
Ordinary shares issued to acquire Wanchun Pharma 2,400
Deemed contribution through the Internal Restructuring 9,393
Initial public offering costs accrued in accrued expenses 1,324
Net settlement of related party loans $ 1,800